Fig. 6: Association between demographic, cellular and transcriptomic parameters and vaccine responsiveness after the exclusion of non-informative donors.
a, Ridge plot displaying the distribution of before and after vaccination OPA titers for each serotype in the PCV13 (n = 19) and PPSV23 (n = 20) cohorts. Note that baseline titer levels vary among serotypes. Non-informative donors were identified using a published strategy, and associations were recalculated after exclusion of these donors. b, Association between PCV13 (n = 16) and PPSV23 (n = 18) strength and age (in years). c, Sex differences in PCV13 (n = 16) and PPSV23 (n = 18) vaccine responses. Note that women mount significantly stronger responses to the PCV13 vaccine. d, Association between TH1 and TH17 cell percentages at baseline and PCV13 (n = 15) and PPSV23 (n = 17) vaccine responsiveness. e, Correlations between CYTOX scores at baseline and PCV13 (n = 12) and PPSV23 (n = 14) vaccine responsiveness (left) and correlations between the baseline expression of NCAM1, GNLY and PRF1 and PCV13 and PPSV23 vaccine responsiveness (right). f, Baseline abundance of CD16+ NK cells in PCV13 SRs (n = 6) and WRs (n = 3). Correlation analyses were computed using the Pearson correlation metric (b and d–f), and P values were computed by using two-sided t-tests. Box plots display the median and IQR (25–75%), with whiskers representing the upper and lower quartiles ±1.5× IQR. A Wilcoxon rank-sum test (two sided) was used to compare strength, extent and rank between men and women treated with PCV13 and PPSV23 (c); n represents the number of biological replicates.
